ResBiotic Nutrition reveals resB’s “positive effects of structure and function” on lung health
25 May 2022 --- ResBiotic Nutrition Inc, a microbiome-based nutrition company pioneering probiotics for gut, lung and immune health, has presented preclinical data from a study of resB Lung Support, the first science-backed probiotic and herbal supplement for lung health.
The data landed at Digestive Disease Week 2022 in San Diego, California, suggesting that resB Lung Support works effectively against key inflammatory markers in the lungs.
“These important findings reaffirm the role of our proprietary blend of probiotic strains and bioactive botanical extracts in targeting the gut-lung axis,” says founder and CEO Vivek Lal.
“After studying the microbiome as it relates to lung health, for more than a decade, we’re eager to present these initial data showing positive effects of resB on lung structure and function.”
The research focused on the gut-lung axis.“Positively impacting lung health”
Researchers investigated the effects of oral administration with resB to positively impact lung health by reducing inflammation and damage induced by a bacterial imbalance or dysbiosis.
Results from in vitro models showed that oral supplementation with resB is associated with a decrease in MMP-9 inflammatory pathway activity, associated with tissue damage and neutrophilic inflammation.
In the in vivo models of dysbiosis and lung tissue damage, oral resB administration leads to improved lung structure and reduced neutrophilic inflammation.
“With these preliminary findings, we are pleased to contribute to the growing body of evidence around the gut-lung axis and look forward to sharing complete results on lung health and results from future studies supporting its role in lung, digestion and immune function,” explains Lal.
Further research warranted
ResBiotic is conducting further clinical trials to test the effects of taking resB Lung Support formulation in human populations.
Ongoing clinical trials look at the effects of resB in healthy people, smokers, and people with asthma; quality of life in patients with chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis; and pneumonia incidence and prognosis in acute care settings.
According to a recent Gut Microbes-published study, probiotics have been linked to fewer respiratory symptoms in obese middle-aged adults.
Last April, Resbiotic Inc. landed US$3 million of seed funding, which will support the development and commercialization of probiotic formulations for lung health.
Gaia Herbs also previously launched a range of herbal products touted for supporting respiratory health.
Edited by Elizabeth Green
